---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-050363"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T12:41:03.209742+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Leap Therapeutics to present updated DKN-01/Gastric Cancer data at ASCO 2023

## Summary
- Will present long-term follow-up data from Part A of Phase 2 DisTinGuish study at ASCO June 2-6, 2023.
- Presentation scheduled for June 5, 2023, at 11:30 a.m. ET; abstract #4027, poster discussion session.
- Study combines DKN-01 (anti-DKK1) + tislelizumab + chemo in first-line advanced GEA; Part A enrolled 25 pts.
- Ongoing Part C enrolling ~160 first-line HER2- GEA pts in randomized controlled trial.

## SEC filing metadata
- accession: 0001104659-23-050363
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923050363/0001104659-23-050363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923050363/tm2313816d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-050363
- JSON: https://secwatch.observer/filing/0001104659-23-050363.json
- Plain text: https://secwatch.observer/filing/0001104659-23-050363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.